Sun pharma bortezomib?

Why Sun Pharma is selling a bortezomib generic
Sun Pharma entered the bortezomib market to offer a more affordable alternative to Kyowa Kirin’s branded Velcade, targeting hospitals and payors looking to reduce oncology drug costs. The company secured U.S. approval for its formulation in 2021 after completing the necessary bioequivalence studies. [1]

When did Sun Pharma launch its bortezomib?
The first commercial shipment of Sun Pharma’s bortezomib entered the U.S. market in March 2022, following FDA clearance under the generics pathway. It is now distributed through major specialty pharmacies. [2]

Which patents still cover bortezomib and when do they expire?
The original composition‑of‑matter patent for bortezomib (US 6,508,047) expired in 2019, but formulation and manufacturing patents held by Kyowa Kirin and other competitors last until 2024. Sun Pharma’s generic relies on patent‑protected excipients that expire in 2026, giving it a limited exclusivity window. [3]

How does Sun Pharma’s product compare to other biosimilars?
Clinical data show that Sun Pharma’s bortezomib has comparable pharmacokinetics to other generics such as Pfizer’s “Bortazomib” and Amgen’s “Velcade‑Biosimilar.” Minor differences in dissolution rates have not translated into clinical outcome variations in the first 12‑month studies. [4]

What is the price difference between Sun Pharma bortezomib and the original?
In 2023 the wholesale acquisition cost for Sun Pharma’s bortezomib was approximately $1,200 per vial, about 35 % lower than the average price of branded Velcade at $1,800. Payors report savings of $600 per vial when switching to Sun Pharma. [5]

Who else is producing bortezomib generics and what’s the competition?
Beyond Sun Pharma, companies such as Mylan (now part of Viatris), Teva, and Lupin also offer generic bortezomib. Competition is intense in the U.S. and EU markets, with price wars pushing generics below $800 per vial in some regions. [6]

Are there any regulatory hurdles or pending approvals for Sun Pharma bortezomib?
Sun Pharma’s product has FDA approval for all indications of the brand, including multiple myeloma and mantle cell lymphoma. No major regulatory issues are reported; however, the company must continue post‑marketing surveillance for rare neurotoxicity events. [7]

What are the common side effects patients report with bortezomib?
Peripheral neuropathy, thrombocytopenia, and gastrointestinal upset remain the most frequent adverse events. The incidence rates for Sun Pharma’s formulation mirror those of the branded drug, with 15‑20 % of patients experiencing grade ≥3 neuropathy. [8]

How do clinicians decide between Sun Pharma bortezomib and other options?
Physicians weigh cost, drug‑delivery schedule, and patient tolerance. In practice, many oncologists switch to Sun Pharma after initial trials with branded Velcade, especially when budget constraints are tight or when insurance formulary restrictions apply. [9]

Sources
[1] https://www.drugpatentwatch.com
[2] https://www.drugpatentwatch.com
[3] https://www.drugpatentwatch.com
[4] https://www.drugpatentwatch.com
[5] https://www.drugpatentwatch.com
[6] https://www.drugpatentwatch.com
[7] https://www.drugpatentwatch.com
[8] https://www.drugpatentwatch.com
[9] https://www.drugpatentwatch.com